Multiomics

Genomics
#Clinical trials #Drug discovery #Genetics / genomics #Multiomics

Designing multiomics studies to capture biological response

Dr Shi-qi An and Dr Naira Movsisyan of Novogene Europe consider why multiomics studies should follow biological responses over time, and how carefully chosen sampling points can distinguish initiating mechanisms from adaptation, compensation and the molecular signatures left by surviving cells.  In drug discovery, a compound is often assessed by… Read More

#Exclusive Content

#Cambridge Omics Centre #Drug discovery #Metabolomics #Multiomics #Novogene Europe

Novogene Europe launches untargeted metabolomics service

Multiomics research services partner Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the UK and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome and broader life science studies. Untargeted Metabolomics… Read More

#News

#AI #Drug discovery #Genomics #Multiomics #Transcriptomics

Advances in genomics for drug discovery 

DDW Editor Reece Armstrong speaks to Michelle Carlson about overall advances in genomics and the integration of emerging technologies to create more drug discovery and development opportunities.  RA: How is long-read sequencing enabling greater clinical research… Read More

#Exclusive Content

#Multiomics

From plasma to prediction: Mapping disease trajectories with proteomics at unprecedented scale – on-demand webinar with Standard BioTools Feb 2026

What if you could see disease coming years before symptoms appear?   Chronos makes that vision a reality. Built on 100 million plasma samples from six million US donors, this platform combines real-world clinical data with high-resolution proteomics to chart molecular changes across time and populations.  In this webinar, hosted… Read More

#Webinars

#Drug discovery #Multiomics

Webinar – MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases.  End-to-end solutions range from sourcing and managing samples to standardised preparation, cutting-edge mass spectrometry, and advanced in-house data analysis. What’s more, tailored MS-based assays enable high resolution or high throughput… Read More

#Webinars

#Biomarkers #Listicle #Multiomics #Video

New listicle: How biomarkers are reducing risk in drug discovery

Watch this DDW listicle exploring how biomarkers are reducing risk in drug discovery and clinical trials, sponsored by Olink. As drug development becomes increasingly complex, smarter decisions depend on having the right biological data at the right time. In this video, hosted by Drug Discovery World (DDW) and… Read More

#News

#Drug discovery #Multiomics

Webinar – Unbiased exploration of biological systems: Leveraging untargeted metabolomics and lipidomics for drug discovery

This webinar, hosted by DDW and supported by Evotec, will introduce untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar will begin with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular… Read More

#Webinars

Antique clock
#Age-related diseases (ARDs) #Ageing #Epigenetics #Healthspan #Multiomics #Rejuvenation therapies

Turning back the epigenetic clock: Can we reverse ageing?

In this article, based on a session at Life Sciences Baltics 2025, Diana Turner reviews the latest research into epigenetics and rejuvenation.  An epigenetic clock is a biomarker of ageing that can be used to estimate ‘biological age’. The method relies on the modifications to DNA that… Read More

#Exclusive Content

#Drug discovery #Multi-omics #Multiomics #Nanopore sequencing #QA/QC

Guide: Sequencing solutions for more confident decision-making

Discover sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform — and enabling faster, more confident decision-making. In this new getting started Guide from Oxford Nanopore Technologies, you will: Find out how Oxford Nanopore… Read More

#News

#Drug discovery #Multi-omics #Multiomics #Nanopore sequencing #QA/QC

Oxford Nanopore sequencing solutions for biopharma

Discover sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform — and enabling faster, more confident decision-making. In this new getting started guide, you will: Find out how Oxford Nanopore sequencing delivers the multiomic insight… Read More

#Guides #Resources

#AI / data analytics / healthtech / informatics #Drug discovery #Multiomics #Partnership

MoU signed to advance precision medicine growth in Serbia 

MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company, and BIO4 Campus (BIO4), the Republic of Serbia’s flagship biotechnology and life sciences hub, have announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications. Read More

#Business & Investment #News

#Advanced Therapies #Drug discovery #Multiomics

White Paper – Accelerating Pharma Innovation and Drug Discovery with 5D Multiomics

Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. AVITI24™ 5D multiomics platform offers a new path by capturing RNA,… Read More

#Whitepapers

#Diagnostics #Genetics / genomics #Multiomics #Personalised medicine

The power of multiomic integration in diagnostics and drug discovery

DDW’s Megan Thomas speaks with Dr Madhuri Hegde, Senior Vice President and Chief Scientific Officer at Revvity Omics, about how the integration of multiomics is advancing companion diagnostics and personalised medicine. MT: How is the integration of multiomics transforming the landscape of companion diagnostics? MH: We see multiomics as a… Read More

#Exclusive Content